Accelerate your SDTM Mapping with Pinnacle 21 Enterprise Plus
Streamline your SDTM mapping with Pinnacle 21 Enterprise. Discover how innovation and efficiency enhance data…
CertaraAugust 13, 2025
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…
CertaraAugust 13, 2025
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial
Explore updated results from the Phase 3 TROPiCS-02 trial of Sacituzumab Govitecan in advanced HR+/HER2–…
CertaraAugust 13, 2025
Differences between eCTD 4.0 and eCTD 3.2.2 Submissions – What You Need to Know
Access our on-demand webinar to explore the key differences between eCTD 4.0 and eCTD 3.2.2.…
CertaraAugust 11, 2025
Regulatory Operations Best Practices for Health Canada Submissions
Health Canada submissions now require eCTD/CESG; regulatory operations expert support can streamline the process and…
CertaraAugust 11, 2025
Certara Announces D360 25.5 Release, Featuring Dynamic Data Subsets and Enhanced Analytics
D360 v25.5 allows scientists to divide up a dataset into series of compounds & perform…
CertaraAugust 7, 2025
Certara Reports Second Quarter 2025 Financial Results
RADNOR, PA— August 6, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development,…
CertaraAugust 6, 2025
Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development
Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…
CertaraAugust 6, 2025
Modeling Approaches for Determination of Pharmacokinetics/Pharmacodynamics
Explore insights from Certara experts on how PK/PD modeling streamlines biologic drug development.
CertaraAugust 5, 2025
